Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus
Kaposi’s Sarcoma (KS) is a neoplasm derived from endothelial cells and is associated with human herpesvirus-8 (HHV-8) infection. It is mostly seen in patients suffering from AIDS and/or chronic immunosuppression. Currently, systemic chemotherapy is the primary treatment option for the advanced KS. H...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.907345/full |
| _version_ | 1818551605933375488 |
|---|---|
| author | Min Lin Renwei Luo Peng Zhang Zhixun Xiao Ting Gong Chao Ji |
| author_facet | Min Lin Renwei Luo Peng Zhang Zhixun Xiao Ting Gong Chao Ji |
| author_sort | Min Lin |
| collection | DOAJ |
| description | Kaposi’s Sarcoma (KS) is a neoplasm derived from endothelial cells and is associated with human herpesvirus-8 (HHV-8) infection. It is mostly seen in patients suffering from AIDS and/or chronic immunosuppression. Currently, systemic chemotherapy is the primary treatment option for the advanced KS. However, there is no consensus on the treatment of KS. In this case, an 84-year-old man with a history of psoriasis developed multiple painful dark purple nodules on the trunk and extremities during the treatment of drug reaction with eosinophilia and systemic symptoms (DRESS). KS was confirmed by the skin biopsy, and the immunohistochemical staining demonstrated the positivity for HHV-8 while the anti-HIV test was negative. The patient then received anlotinib treatment, a tyrosine kinase inhibitor, for 5 months, and his skin lesions subsided. This case indicates that anlotinib may be a potential treatment option for KS. |
| first_indexed | 2024-12-12T09:02:07Z |
| format | Article |
| id | doaj.art-99469c6eec5745c490a51a37d71629df |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-12T09:02:07Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-99469c6eec5745c490a51a37d71629df2022-12-22T00:29:48ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-05-01910.3389/fmed.2022.907345907345Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory TragusMin Lin0Renwei Luo1Peng Zhang2Zhixun Xiao3Ting Gong4Chao Ji5Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaCentral Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaKaposi’s Sarcoma (KS) is a neoplasm derived from endothelial cells and is associated with human herpesvirus-8 (HHV-8) infection. It is mostly seen in patients suffering from AIDS and/or chronic immunosuppression. Currently, systemic chemotherapy is the primary treatment option for the advanced KS. However, there is no consensus on the treatment of KS. In this case, an 84-year-old man with a history of psoriasis developed multiple painful dark purple nodules on the trunk and extremities during the treatment of drug reaction with eosinophilia and systemic symptoms (DRESS). KS was confirmed by the skin biopsy, and the immunohistochemical staining demonstrated the positivity for HHV-8 while the anti-HIV test was negative. The patient then received anlotinib treatment, a tyrosine kinase inhibitor, for 5 months, and his skin lesions subsided. This case indicates that anlotinib may be a potential treatment option for KS.https://www.frontiersin.org/articles/10.3389/fmed.2022.907345/fullKaposi’s Sarcomaanlotinibtyrosine kinase inhibitorsHHV-8DRESS |
| spellingShingle | Min Lin Renwei Luo Peng Zhang Zhixun Xiao Ting Gong Chao Ji Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus Frontiers in Medicine Kaposi’s Sarcoma anlotinib tyrosine kinase inhibitors HHV-8 DRESS |
| title | Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus |
| title_full | Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus |
| title_fullStr | Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus |
| title_full_unstemmed | Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus |
| title_short | Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus |
| title_sort | case report successful treatment of kaposi s sarcoma with anlotinib in an hiv negative patient after the treatment of drug reaction with eosinophilia and systemic symptoms accessory tragus |
| topic | Kaposi’s Sarcoma anlotinib tyrosine kinase inhibitors HHV-8 DRESS |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.907345/full |
| work_keys_str_mv | AT minlin casereportsuccessfultreatmentofkaposissarcomawithanlotinibinanhivnegativepatientafterthetreatmentofdrugreactionwitheosinophiliaandsystemicsymptomsaccessorytragus AT renweiluo casereportsuccessfultreatmentofkaposissarcomawithanlotinibinanhivnegativepatientafterthetreatmentofdrugreactionwitheosinophiliaandsystemicsymptomsaccessorytragus AT pengzhang casereportsuccessfultreatmentofkaposissarcomawithanlotinibinanhivnegativepatientafterthetreatmentofdrugreactionwitheosinophiliaandsystemicsymptomsaccessorytragus AT zhixunxiao casereportsuccessfultreatmentofkaposissarcomawithanlotinibinanhivnegativepatientafterthetreatmentofdrugreactionwitheosinophiliaandsystemicsymptomsaccessorytragus AT tinggong casereportsuccessfultreatmentofkaposissarcomawithanlotinibinanhivnegativepatientafterthetreatmentofdrugreactionwitheosinophiliaandsystemicsymptomsaccessorytragus AT chaoji casereportsuccessfultreatmentofkaposissarcomawithanlotinibinanhivnegativepatientafterthetreatmentofdrugreactionwitheosinophiliaandsystemicsymptomsaccessorytragus |